Status:
UNKNOWN
Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Effects of Chemotherapy
Eligibility:
All Genders
16-60 years
Phase:
PHASE2
Brief Summary
To imporve the outcome of patients with relapsed/refractory lymphoma, we conduct a clinical trial to test the efficacy and feasibility of consolidation chemotherapy after autologous stem cell transpla...
Detailed Description
Patients with relapsed or refractory lymphoma will be included. All patients will undergo PBSC mobilization with CTX and G-CSF. After sucessful collection of CD34+ over 1x109/L, autologous stem cel lt...
Eligibility Criteria
Inclusion
- Patients with relapsed or refracotry NHL or HD: PR or SD after first line salvage chemotherapy;
- ECOG: 0-2
- Tbil \< 1.5x ULN and AST/ALT \<2.5x ULN
- With informed consent
Exclusion
- Life expectancy \< 3 months
- Women in pregnancy
- uncontrollable infection disease
- serum Cr \>400mmol/l
- uncontroled diabetis and heart disease
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02306837
Start Date
September 1 2014
End Date
September 1 2019
Last Update
September 8 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Rui Jin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, China, 200025
2
Shanghai No 10 Hospital
Shanghai, China